Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort StudyResearch article Published on 2022-05-162022-10-05 Journal: Current Therapeutic Research [Category] 신약개발, 임상, 치료법, [키워드] Adverse reaction Clin clinical coronavirus disease COVID-19 CT-P59 death deaths Deterioration discharged efficacy end point Exp Fever Hospitalization indicate mechanical ventilation median time Mild-to-moderate oxygen oxygen saturation p value Patient patients deteriorating patients with COVID-19 performed peripheral capillary phase Placebo Prevent proportion reduced regdanvimab Remdesivir required Result retrospective cohort study Retrospective study risk SARS-CoV-2 single hospital SOC Standard of care sustained treated Two patient [DOI] 10.1016/j.curtheres.2022.100675 [Article Type] Research article
The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A ReviewReview article Published on 2021-12-152022-10-05 Journal: Current Therapeutic Research [Category] 바이오마커, 변종, 치료법, [키워드] anti-inflammatory cytokines Anti-inflammatory effects Bruton tyrosine kinase inhibitor BTK BTK inhibitor caused Clin clinician Complication Coronavirus disease 2019 COVID-19 cytokine level Cytokine release syndrome Cytokines develop disease Effect Effectiveness Elsevier evaluate Exp immune response Inflammation Inflammatory cytokines information journal kinase less management medication Mortality Novel coronavirus objective pandemic Pathogenesis pathogenesis of COVID-19 pathway Patient patients patients with COVID-19 provide receiving reduce Result review role SARS-CoV-2 Serum level Severe case severe respiratory illness Signaling Spread subsequent Support the disease treating COVID-19 Treatment tyrosine Web of Science [DOI] 10.1016/j.curtheres.2021.100658 [Article Type] Review article
The early interferon catches the SARS-CoV-2초기 인터페론은 SARS-CoV-2를 잡습니다.Comment Published on 2021-10-042022-09-11 Journal: The Journal of Experimental Medicine [Category] SARS, 치료제, [키워드] Antiviral Biomarker Biomarkers epithelial cell epithelial cells Exp growth Infection inhibit SARS-CoV-2 innate antiviral immunity interferon interferons mucosa mucosal nasopharyngeal the SARS-CoV-2 [DOI] 10.1084/jem.20211667 PMC 바로가기 [Article Type] Comment